Mismatch repair deficiency and response to immune checkpoint blockade

Research output: Contribution to journalReview article

Abstract

More than 1.6 million new cases of cancer will be diagnosed in the U.S. in 2016, resulting in more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in advanced cancers, immunotherapy development, particularly with PD-1 inhibitors, has changed the face of treatment for a number of tumor types. One example is the subset of tumors characterized by mismatch repair deficiency and microsatellite instability that are highly sensitive to PD-1 blockade. Hereditary forms of cancer have been noted for more than a century, but the molecular changes underlying mismatch repair-deficient tumors and subsequent microsatellite unstable tumors was not known until the early 1990s. In this review article, we discuss the history and pathophysiology of mismatch repair, the process of testing for mismatch repair deficiency and microsatellite instability, and the role of immunotherapy in this subset of cancers.

Original languageEnglish (US)
Pages (from-to)1200-1211
Number of pages12
JournalOncologist
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Neoplasms
Microsatellite Instability
DNA Mismatch Repair
Immunotherapy
Turcot syndrome
Microsatellite Repeats
History
Drug Therapy
Therapeutics

Keywords

  • Colonic neoplasms
  • Colorectal neoplasms
  • DNA mismatch repair
  • Hereditary nonpolyposis
  • Immunotherapy
  • Microsatellite instability

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mismatch repair deficiency and response to immune checkpoint blockade. / Lee, Valerie; Murphy, Adrian; Le, Dung; Diaz, Luis A.

In: Oncologist, Vol. 21, No. 10, 01.10.2016, p. 1200-1211.

Research output: Contribution to journalReview article

@article{8fcd062ac11c4f3885cb7f2ab429d4a6,
title = "Mismatch repair deficiency and response to immune checkpoint blockade",
abstract = "More than 1.6 million new cases of cancer will be diagnosed in the U.S. in 2016, resulting in more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in advanced cancers, immunotherapy development, particularly with PD-1 inhibitors, has changed the face of treatment for a number of tumor types. One example is the subset of tumors characterized by mismatch repair deficiency and microsatellite instability that are highly sensitive to PD-1 blockade. Hereditary forms of cancer have been noted for more than a century, but the molecular changes underlying mismatch repair-deficient tumors and subsequent microsatellite unstable tumors was not known until the early 1990s. In this review article, we discuss the history and pathophysiology of mismatch repair, the process of testing for mismatch repair deficiency and microsatellite instability, and the role of immunotherapy in this subset of cancers.",
keywords = "Colonic neoplasms, Colorectal neoplasms, DNA mismatch repair, Hereditary nonpolyposis, Immunotherapy, Microsatellite instability",
author = "Valerie Lee and Adrian Murphy and Dung Le and Diaz, {Luis A.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1634/theoncologist.2016-0046",
language = "English (US)",
volume = "21",
pages = "1200--1211",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Mismatch repair deficiency and response to immune checkpoint blockade

AU - Lee, Valerie

AU - Murphy, Adrian

AU - Le, Dung

AU - Diaz, Luis A.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - More than 1.6 million new cases of cancer will be diagnosed in the U.S. in 2016, resulting in more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in advanced cancers, immunotherapy development, particularly with PD-1 inhibitors, has changed the face of treatment for a number of tumor types. One example is the subset of tumors characterized by mismatch repair deficiency and microsatellite instability that are highly sensitive to PD-1 blockade. Hereditary forms of cancer have been noted for more than a century, but the molecular changes underlying mismatch repair-deficient tumors and subsequent microsatellite unstable tumors was not known until the early 1990s. In this review article, we discuss the history and pathophysiology of mismatch repair, the process of testing for mismatch repair deficiency and microsatellite instability, and the role of immunotherapy in this subset of cancers.

AB - More than 1.6 million new cases of cancer will be diagnosed in the U.S. in 2016, resulting in more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in advanced cancers, immunotherapy development, particularly with PD-1 inhibitors, has changed the face of treatment for a number of tumor types. One example is the subset of tumors characterized by mismatch repair deficiency and microsatellite instability that are highly sensitive to PD-1 blockade. Hereditary forms of cancer have been noted for more than a century, but the molecular changes underlying mismatch repair-deficient tumors and subsequent microsatellite unstable tumors was not known until the early 1990s. In this review article, we discuss the history and pathophysiology of mismatch repair, the process of testing for mismatch repair deficiency and microsatellite instability, and the role of immunotherapy in this subset of cancers.

KW - Colonic neoplasms

KW - Colorectal neoplasms

KW - DNA mismatch repair

KW - Hereditary nonpolyposis

KW - Immunotherapy

KW - Microsatellite instability

UR - http://www.scopus.com/inward/record.url?scp=84991735355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991735355&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2016-0046

DO - 10.1634/theoncologist.2016-0046

M3 - Review article

VL - 21

SP - 1200

EP - 1211

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -